Literature DB >> 33725199

Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Lily K Stern1, Michelle M Kittleson2,3.   

Abstract

PURPOSE OF REVIEW: Cardiac amyloidosis is an underrecognized cause of heart failure. We review clinical clues to the diagnoses, a rational approach to testing, and current and emerging therapies. RECENT
FINDINGS: Advances in the diagnosis of amyloid cardiomyopathy include (1) use of 99mtechnetium (99mTc) bone-avid compounds which allow accurate noninvasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in the context of a negative monoclonal light chain screen; and (2) the use of serum and urine immunofixation electrophoresis with serum free light chains as an accurate first diagnostic step for light chain cardiac amyloidosis (AL-CM). Advances in treatment include tafamidis for ATTR-CM and immunologic therapies for AL-CM. With the advent of accurate noninvasive diagnostic modalities and effective therapies, early recognition of cardiac amyloidosis is paramount to implement a diagnostic algorithm and expeditiously institute effective therapies to minimize morbidity and mortality.

Entities:  

Keywords:  Cardiac amyloidosis; Light chain amyloidosis; Monoclonal light chains; Tafamidis; Technetium pyrophosphate scan; Transthyretin amyloidosis

Mesh:

Substances:

Year:  2021        PMID: 33725199     DOI: 10.1007/s11912-021-01028-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  88 in total

Review 1.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Authors:  Rodney H Falk; Kevin M Alexander; Ronglih Liao; Sharmila Dorbala
Journal:  J Am Coll Cardiol       Date:  2016-09-20       Impact factor: 24.094

2.  Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.

Authors:  Robert A Kyle; Dirk R Larson; Paul J Kurtin; Shaji Kumar; James R Cerhan; Terry M Therneau; S Vincent Rajkumar; Celine M Vachon; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2019-01-31       Impact factor: 7.616

3.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Authors:  Thirusha Lane; Marianna Fontana; Ana Martinez-Naharro; Candida Cristina Quarta; Carol J Whelan; Aviva Petrie; Dorota M Rowczenio; Janet A Gilbertson; David F Hutt; Tamer Rezk; Svetla G Strehina; Joan Caringal-Galima; Richa Manwani; Faye A Sharpley; Ashutosh D Wechalekar; Helen J Lachmann; Shameem Mahmood; Sajitha Sachchithanantham; Edmund P S Drage; Harvey D Jenner; Rosie McDonald; Ottavia Bertolli; Alan Calleja; Philip N Hawkins; Julian D Gillmore
Journal:  Circulation       Date:  2019-05-21       Impact factor: 29.690

4.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.

Authors:  Martha Grogan; Christopher G Scott; Robert A Kyle; Steven R Zeldenrust; Morie A Gertz; Grace Lin; Kyle W Klarich; Wayne L Miller; Joseph J Maleszewski; Angela Dispenzieri
Journal:  J Am Coll Cardiol       Date:  2016-09-06       Impact factor: 24.094

5.  A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Authors:  Eli Muchtar; Morie A Gertz; Robert A Kyle; Martha Q Lacy; David Dingli; Nelson Leung; Francis K Buadi; Suzanne R Hayman; Prashant Kapoor; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; S Vincent Rajkumar; Shaji K Kumar; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2019-02-13       Impact factor: 7.616

6.  Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.

Authors:  R A Kyle; A Linos; C M Beard; R P Linke; M A Gertz; W M O'Fallon; L T Kurland
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

7.  Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.

Authors:  Merrill D Benson; Joel N Buxbaum; David S Eisenberg; Giampaolo Merlini; Maria J M Saraiva; Yoshiki Sekijima; Jean D Sipe; Per Westermark
Journal:  Amyloid       Date:  2019-01-07       Impact factor: 7.141

8.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.

Authors:  Maarit Tanskanen; Terhi Peuralinna; Tuomo Polvikoski; Irma-Leena Notkola; Raimo Sulkava; John Hardy; Andrew Singleton; Sari Kiuru-Enari; Anders Paetau; Pentti J Tienari; Liisa Myllykangas
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

9.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation.

Authors:  G G Cornwell; W L Murdoch; R A Kyle; P Westermark; P Pitkänen
Journal:  Am J Med       Date:  1983-10       Impact factor: 4.965

10.  Light Chain (AL) Amyloidosis: The Journey to Diagnosis.

Authors:  Kristen L McCausland; Michelle K White; Spencer D Guthrie; Tiffany Quock; Muriel Finkel; Isabelle Lousada; Martha S Bayliss
Journal:  Patient       Date:  2018-04       Impact factor: 3.883

View more
  9 in total

1.  Heart Failure, Precision Medicine, and Incremental Equity: The Case of Hereditary Amyloid Cardiomyopathy.

Authors:  Melvin R Echols; Herman Taylor
Journal:  JAMA       Date:  2022-04-12       Impact factor: 157.335

Review 2.  Cardiac Amyloidosis Treatment.

Authors:  Lily K Stern; Jignesh Patel
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

Review 3.  Multimodality Imaging in the Evaluation and Prognostication of Cardiac Amyloidosis.

Authors:  Paul J Scheel; Monica Mukherjee; Allison G Hays; Joban Vaishnav
Journal:  Front Cardiovasc Med       Date:  2022-03-24

Review 4.  Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.

Authors:  Katrine Bay; Finn Gustafsson; Michael Maiborg; Anne Bagger-Bahnsen; Anne Mette Strand; Trine Pilgaard; Steen Hvitfeldt Poulsen
Journal:  ESC Heart Fail       Date:  2022-03-27

Review 5.  Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia.

Authors:  Weiqin Lin; Pairoj Chattranukulchai; Alex Pw Lee; Yen-Hung Lin; Wen-Chung Yu; Houng-Bang Liew; Abraham Oomman
Journal:  Clin Cardiol       Date:  2022-07-06       Impact factor: 3.287

Review 6.  The Role of Echocardiogram and Cardiac Rhythm Analysis for Early Detection of Cardiac Amyloidosis.

Authors:  Elizabeth Hubert; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2022-10-12

7.  Cardiac Amyloidosis-Challenging Diagnosis and Unclear Clinical Picture.

Authors:  Sylwia Kozak; Krzysztof Ulbrich; Maciej Migacz; Krzysztof Szydło; Katarzyna Mizia-Stec; Michał Holecki
Journal:  Medicina (Kaunas)       Date:  2021-05-06       Impact factor: 2.430

8.  Nomogram Model for Dynamic and Individual Prediction of Cardiac Response and Survival for Light Chain Amyloidosis in 737 Patients With Cardiac Involvement.

Authors:  Yang Li; Yanze Cao; Mingxin Zheng; Jiaqi Hu; Wei Yan; Xiaoyu Liu; Aijun Liao; Wei Yang; Jian Li; Huihan Wang
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

Review 9.  Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.

Authors:  Mi-Hyang Jung; Suyon Chang; Eun Ji Han; Jong-Chan Youn
Journal:  Diagnostics (Basel)       Date:  2022-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.